Miraculins Moves Closer To Commercialization 02
Post# of 6
Posted On: 02/09/2015 11:33:32 AM
Miraculins Moves Closer To Commercialization
02/09/2015 [ACCESSWIRE]
WHITEFISH, MT / ACCESSWIRE / February 9, 2015 / Diabetes is the seventh leading cause of death in the United States with over a million new cases each year, according to the American Diabetes Association, costing the healthcare system $176 billion in direct costs and the economy $76 billion in lost productivity in 2012.
The metabolic disease is characterized by the body's inability to produce enough insulin, or more commonly, to not be able to effectively use the insulin it does produce, both of which cause elevated and damaging glucose levels in the blood. While companies like Eli Lilly & Co. (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) provide artificial insulin to fill the void, there are no cures for diabetes that alleviate a patient's need for costly lifelong treatment. One of the best ways to prevent or slow down the onset of diabetes and its disastrous complications is to make dietary and lifestyle changes that inhibit its formation from the start.
Unfortunately, it's difficult to predict when diabetes is becoming a major risk as you can have it for years without any symptoms while it causes unseen internal damage. Pre-diabetes affects some 86 million Americans over the age of 20 (9 out of 10 are undiagnosed), but the only way to diagnose it is through invasive blood testing. Patients often delay undergoing these tests, which means that the preventable stage of the disease is often ignored and undiagnosed until it's too late and full-blown diabetes is developed requiring lifelong treatment.
The Advantages of a Non-Invasive Test
Miraculins Inc. (TSX-V: MOM) (OTC: MCUIF), a medical device company that acquires, develops and commercializes non-invasive screening tests to aid physicians in the earlier diagnosis of disease, is introducing a non-invasive diabetes screening test that takes just 90 seconds to complete. It has the potential to affect real change by making early diabetes screening easily accessible without requiring needles, blood draw, fasting, or waiting and by creating a tipping point for action, motivating patients at risk to seek medical care and attention before the disease becomes uncontrollable.
http://www.accesswire.com/viewarticle.aspx?id=425706
02/09/2015 [ACCESSWIRE]
WHITEFISH, MT / ACCESSWIRE / February 9, 2015 / Diabetes is the seventh leading cause of death in the United States with over a million new cases each year, according to the American Diabetes Association, costing the healthcare system $176 billion in direct costs and the economy $76 billion in lost productivity in 2012.
The metabolic disease is characterized by the body's inability to produce enough insulin, or more commonly, to not be able to effectively use the insulin it does produce, both of which cause elevated and damaging glucose levels in the blood. While companies like Eli Lilly & Co. (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) provide artificial insulin to fill the void, there are no cures for diabetes that alleviate a patient's need for costly lifelong treatment. One of the best ways to prevent or slow down the onset of diabetes and its disastrous complications is to make dietary and lifestyle changes that inhibit its formation from the start.
Unfortunately, it's difficult to predict when diabetes is becoming a major risk as you can have it for years without any symptoms while it causes unseen internal damage. Pre-diabetes affects some 86 million Americans over the age of 20 (9 out of 10 are undiagnosed), but the only way to diagnose it is through invasive blood testing. Patients often delay undergoing these tests, which means that the preventable stage of the disease is often ignored and undiagnosed until it's too late and full-blown diabetes is developed requiring lifelong treatment.
The Advantages of a Non-Invasive Test
Miraculins Inc. (TSX-V: MOM) (OTC: MCUIF), a medical device company that acquires, develops and commercializes non-invasive screening tests to aid physicians in the earlier diagnosis of disease, is introducing a non-invasive diabetes screening test that takes just 90 seconds to complete. It has the potential to affect real change by making early diabetes screening easily accessible without requiring needles, blood draw, fasting, or waiting and by creating a tipping point for action, motivating patients at risk to seek medical care and attention before the disease becomes uncontrollable.
http://www.accesswire.com/viewarticle.aspx?id=425706
(0)
(0)Miraculins Inc. (MCUIF) Stock Research Links
Scroll down for more posts ▼